NCT07320963尚未招募1 期
A Prospective, Single-Arm, Phase Ib/II Clinical Trial of Chidamide in Combination With Toripalimab and Anlotinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Failed at Least One Prior Line of Therapy
Sun Yat-sen University0 个研究点目标入组 52 人开始时间: 2026年3月31日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 52
- 主要终点
- MTD
研究概览
简要总结
To explore and evaluate the dose-limiting toxicity (DLT) profile of the fixed-dose combination of toripalimab, anlotinib, and chidamide in patients with recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), and to determine the maximum tolerated dose (MTD) of chidamide, thereby informing subsequent clinical dosing regimens.
To assess the objective response rate (ORR) of the combination regimen in this patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: ≥18 years and ≤70 years, gender unrestricted.
- •Diagnosis: Histologically/pathologically confirmed metastatic nasopharyngeal carcinoma (NPC) that has failed at least one prior line of therapy (including cisplatin-containing regimens) or is intolerant to existing therapies (relapse within 6 months after completion of adjuvant/neoadjuvant concurrent chemoradiotherapy is eligible).
- •3. Performance Status: ECOG performance status 0-
- •Measurable Disease: At least one measurable lesion per RECIST 1.1 criteria.
- •Prior Immunotherapy:
- •Patients who have received PD-1, PD-L1, PD-L2, or CTLA-4 inhibitors, or other therapies targeting T-cell co-stimulation/checkpoint pathways:
- •Must have achieved complete response (CR), partial response (PR), or stable disease (SD) ≥6 months during treatment.
- •Only one prior immunotherapy regimen is allowed (e.g., neoadjuvant and adjuvant regimens using the same immunotherapy are considered one regimen).
- •Switching to a different immunotherapy regimen for non-immunotherapy-related progression is permissible if cumulative SD duration ≥6 months.
- •6. Organ Function:
- •Hematology:
- •ANC ≥1.5×10⁹/L, PLT ≥75×10⁹/L, Hb ≥90 g/L. No blood product transfusion or growth factor support (e.g., G-CSF, EPO) within 2 weeks prior to screening.
- •Hepatology:
- •TBIL ≤1.5×ULN; ALT/AST ≤2.5×ULN (≤5×ULN if liver metastases present).
- •Renal Function:
- •Serum Cr ≤1.5×ULN or CrCl >60 mL/min.
- •Thyroid Function:
- •TSH, FT4, FT3 within CTC AE Grade 0-
- •Survival Expectancy: ≥3 months.
- •Informed Consent: Voluntary participation and signed written informed consent.
排除标准
- •Known severe hypersensitivity (≥Grade 3) to any monoclonal/polyclonal antibody, chidamide, or anlotinib components.
- •Necrotic lesions identified within 4 weeks prior to enrollment, with investigator-judged risk of major bleeding.
- •Chemotherapy, targeted therapy, or immunomodulatory agents (including thymosin, interferon, IL-2, etc.) within 2 weeks prior to enrollment.
- •Washout period determined by clinical resolution of adverse events (AEs) and prior treatment regimens.
- •Palliative radiotherapy to localized lesions within 4 weeks prior to enrollment, unless the lesion is non-target and other measurable target lesions exist.
- •Grade ≥3 irAEs during prior immunotherapy.
- •Prior treatment with HDAC inhibitors or anti-angiogenic agents.
- •Urine protein ≥2+ or 24-hour urinary protein ≥1 g.
- •Systolic BP >140 mmHg or diastolic BP >90 mmHg despite treatment.
- •Persistent toxicity from prior antitumor therapy (per NCI CTCAE v5.0) >Grade 1, excluding: alopecia, Grade 2 fatigue, Grade 2 anemia, or asymptomatic lab abnormalities.
- •Symptomatic CNS metastases (e.g., edema, steroid requirement) or leptomeningeal disease.
- •Systemic immunosuppressive drugs (excluding topical/inhaled corticosteroids or physiological doses ≤10 mg/day prednisone equivalent) or corticosteroids for contrast allergy within 4 weeks prior to enrollment.
- •Active autoimmune diseases (e.g., interstitial pneumonia, colitis, thyroiditis) or history of severe autoimmune conditions requiring systemic therapy.
- •Exceptions: Vitiligo, childhood asthma (resolved without treatment), or mild asthma managed without bronchodilators.
- •Ongoing anti-tuberculosis therapy or treatment within 1 year prior to screening.
- •Conditions requiring long-term immunosuppressive therapy or systemic corticosteroids at immunosuppressive doses.
- •Severe Cardiac Disease or Significant Cardiac Symptoms.
- •Other Circumstances Deemed Unsuitable by the Investigator
研究组 & 干预措施
Chidamide , Toripalimab and Anlotinib
Experimental
干预措施: Chidamide (Drug)
Chidamide , Toripalimab and Anlotinib
Experimental
干预措施: Toripalimab (Biological)
Chidamide , Toripalimab and Anlotinib
Experimental
干预措施: Anlotinib (Drug)
结局指标
主要结局
MTD
时间窗: 2 years
Objective Response Rate (ORR)
时间窗: 2 years
次要结局
- Progression-Free Survival (PFS)(2 years)
- Duration of response (DoR)(2 years)
- Overall Survival (OS)(2 years)
研究者
Huiqiang Huang
Professor
Sun Yat-sen University
相似试验
招募中
2 期
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) targeting PRAME, as Monotherapy or in Combination with a Checkpoint Inhibitor in Patients with Recurrent and/or Refractory Solid Tumors2022-503133-54-00Immatics Biotechnologies GmbH130
尚未招募
1 期
68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07310355Chengdu StarRay Therapeutics Co., Ltd49
招募中
1 期
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsBreast CancerLung CancerNCT07274852Sichuan Baili Pharmaceutical Co., Ltd.22
已完成
1 期
A Phase I, Single-arm, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult VolunteersBreast CancerNCT07300202Oriplantee Company Limited15
招募中
1 期
A Clinical Trial of P134 Cells in Recurrent GlioblastomaNCT07318818Tasly Pharmaceutical Group Co., Ltd26